BMY Q4 2021 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q4 2021 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$12.0B+8.3% YoY

Gross Profit

$7.2B60.0% margin

Operating Income

$2.2B18.6% margin

Net Income

$2.4B19.8% margin

EPS (Diluted)

$1.07

QoQ Revenue Growth

+3.1%

Cash Flow

Operating Cash Flow

$4.1B

Free Cash Flow

$3.7B

Stock-Based Comp.

$133M

Balance Sheet

Total Assets

$109.3B

Total Liabilities

$73.3B

Stockholders' Equity

$35.9B

Cash & Equivalents

$14.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12.0B	$11.1B	+8.3%
Gross Profit	$7.2B	$6.2B	+15.3%
Operating Income	$2.2B	$731M	+205.6%
Net Income	$2.4B	-$10.0B	+123.7%

Revenue Segments

Revlimid

$3.3B27%

Eliquis

$2.7B22%

Opdivo

$2.0B16%

Mature Products And All Other

$903M7%

Orencia

$864M7%

Pomalyst/Imnovid

$854M7%

Sprycel

$555M5%

Yervoy

$545M4%

Abraxane

$305M2%

Reblozyl

$151M1%

Abecma

$69M1%

Zeposia

$48M0%

Breyanzi

$40M0%

Geographic Segments

UNITED STATES

$7.5B63%

Europe

$2.8B23%

Rest Of World

$1.5B12%

Other Region

$221M2%